ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY

Australian Blood Test Shows Promise for Personalizing PARP Inhibitor Therapy in Ovarian Cancer

- Australian scientists developed a blood test that may better identify ovarian cancer patients likely to respond to PARP inhibitor therapy compared to current standard testing methods. - The SOLACE2 clinical trial involving 15 Australian hospitals demonstrated that immune biomarkers in blood could more effectively guide PARP inhibitor treatment selection than the gold standard HRD test. - The RMIT-patented biomarker signature detects cancer-fighting immune cells and inflammation markers, potentially transforming treatment personalization for over 300,000 women affected by ovarian cancer annually. - While not yet ready for clinical use, the findings published in Nature Communications represent a significant advancement toward more precise ovarian cancer therapy selection.